Viridian Therapeutics (NASDAQ:VRDN) had its "outperform" rating reaffirmed by analysts at Evercore ISI.
Viridian Therapeutics, Inc. (VRDN)
Company Research
Source: MarketBeat
Impact Snapshot
Event Time:
VRDN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VRDN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VRDN alerts
High impacting Viridian Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
VRDN
News
- Hot Picks: Biotech rebound turns to rare disease catalysts [BNN Bloomberg (Canada)]BNN Bloomberg
- Viridian Therapeutics (NASDAQ:VRDN) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $42.00 price target on the stock.MarketBeat
- Viridian Therapeutics (NASDAQ:VRDN) had its price target raised by analysts at Wells Fargo & Company from $26.00 to $29.00. They now have an "equal weight" rating on the stock.MarketBeat
- Viridian Therapeutics: Cautious Optimism As Key Milestones Approach (Rating Downgrade) [Seeking Alpha]Seeking Alpha
- Viridian Therapeutics (NASDAQ:VRDN) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
VRDN
Earnings
- 2/27/25 - Beat
VRDN
Sec Filings
- 1/2/26 - Form 4
- 12/31/25 - Form 144
- 11/14/25 - Form SCHEDULE
- VRDN's page on the SEC website